GB201506388D0 - Site-specific antibody-drug conjugates - Google Patents

Site-specific antibody-drug conjugates

Info

Publication number
GB201506388D0
GB201506388D0 GBGB1506388.6A GB201506388A GB201506388D0 GB 201506388 D0 GB201506388 D0 GB 201506388D0 GB 201506388 A GB201506388 A GB 201506388A GB 201506388 D0 GB201506388 D0 GB 201506388D0
Authority
GB
United Kingdom
Prior art keywords
site
specific antibody
drug conjugates
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1506388.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BERKEL PATRICIUS H C VAN AND CANCER RES TECHNOLOGY Ltd AND HOWARD PHILIP W
Original Assignee
BERKEL PATRICIUS H C VAN AND CANCER RES TECHNOLOGY Ltd AND HOWARD PHILIP W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BERKEL PATRICIUS H C VAN AND CANCER RES TECHNOLOGY Ltd AND HOWARD PHILIP W filed Critical BERKEL PATRICIUS H C VAN AND CANCER RES TECHNOLOGY Ltd AND HOWARD PHILIP W
Priority to GBGB1506388.6A priority Critical patent/GB201506388D0/en
Publication of GB201506388D0 publication Critical patent/GB201506388D0/en
Priority to PCT/EP2016/058377 priority patent/WO2016166305A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
GBGB1506388.6A 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates Ceased GB201506388D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1506388.6A GB201506388D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
PCT/EP2016/058377 WO2016166305A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506388.6A GB201506388D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates

Publications (1)

Publication Number Publication Date
GB201506388D0 true GB201506388D0 (en) 2015-05-27

Family

ID=53333820

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1506388.6A Ceased GB201506388D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates

Country Status (2)

Country Link
GB (1) GB201506388D0 (en)
WO (1) WO2016166305A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6671555B2 (en) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine antibody conjugate
ES2890934T3 (en) 2017-02-08 2022-01-25 Adc Therapeutics Sa Pyrrolobenzodiazepine and antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
JP7402691B2 (en) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム Combination therapy with anti-CD25 antibody drug conjugate
BR112019026498A2 (en) 2017-06-14 2020-07-14 Adc Therapeutics Sa dosing regimens for administration of an anti-cd25 adc
KR102270107B1 (en) 2017-08-18 2021-06-30 메디뮨 리미티드 pyrrolobenzodiazepine conjugate
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065533A2 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
CN105592861A (en) * 2013-08-02 2016-05-18 赛诺菲 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors
AU2014312210A1 (en) * 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Engineered anti-DLL3 conjugates and methods of use

Also Published As

Publication number Publication date
WO2016166305A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
GB201506407D0 (en) Site-specific antibody-drug conjugates
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
GB201506402D0 (en) Site-specific antibody-drug conjugates
GB201506405D0 (en) Site-specific antibody-drug conjugates
GB201506389D0 (en) Site-specific antibody-drug conjugates
GB201506399D0 (en) Site-specific antibody-drug conjugates
ZA201700306B (en) Her2 antibody-drug conjugates
GB201506393D0 (en) Site-specific antibody-drug conjugates
GB201506388D0 (en) Site-specific antibody-drug conjugates
GB201506394D0 (en) Site-specific antibody-drug conjugates
HK1257352A1 (en) Gcc-targeted antibody-drug conjugates
HK1258338A1 (en) Antibody-drug conjugates targeting uparap
GB201512199D0 (en) Site-specific antibody-drug conjugates
GB201512214D0 (en) Site-specific antibody-drug conjugates
GB201512206D0 (en) Site-specific antibody-drug conjugates
GB201512213D0 (en) Site-specific antibody-drug conjugates
GB201512209D0 (en) Site-Specific Antibody-Drug Conjugates
GB201512201D0 (en) Site-specific antibody-drug conjugates
GB201512205D0 (en) Site-specific antibody-drug conjugates
GB201512208D0 (en) Site-specific antibody-drug conjugates
GB201406731D0 (en) Site-specific antibody-drug conjugates
GB201406733D0 (en) Site-specific antibody-drug conjugates
GB201406724D0 (en) Site-specific antibody-drug conjugates
GB201406729D0 (en) Site-specific antibody-drug conjugates
GB201406728D0 (en) Site-specific antibody-drug conjugates

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)